Overview

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects of escalating doses of adoptive T cell therapy in treating patients with stage IV breast cancer. Vaccines are given to patient prior the expansion of a person's white blood cells may help the body build an effective immune response to kill tumor cells that overexpress human epidermal growth factor receptor 2 (HER2)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Washington
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cyclophosphamide
Sargramostim
Vaccines